GoAI
Get started
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$0.88

+$0.029 · +3.41%

Aug 21, 3:55 PM ET

RANI company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

68

Undervalued

Momentum

19

Strong Down

Sentiment

41

Mixed

Risk resilience

32

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Talat Imran
Listed since
Jul 30, 2021
Employees
70

Market position

Volume
708.4K
0.79× average
Average volume
901.78K
Average daily volume
Market cap
57.48M USD
Beta
0.7
Market reference 1

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends629%-1486%-3600%-5715%Gross margin, FY2021: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 44.89%Operating margin, FY2021: -1899.12%Operating margin, FY2024: -5186.19%Operating margin, FY2025: -2345.99%Net margin, FY2021: -306.62%Net margin, FY2024: -2920.04%Net margin, FY2025: -1817.09%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 44.89%. Operating margin FY2021 -1899.12%. Operating margin FY2024 -5186.19%. Operating margin FY2025 -2345.99%. Net margin FY2021 -306.62%. Net margin FY2024 -2920.04%. Net margin FY2025 -1817.09%.

Income trends

Revenue

1.63M USD+58.85%

Operating income

−38.31M USD+28.14%

Net income

−29.67M USD+1.15%
Income trends across reported periods9.6M USD−17.93M USD−45.45M USD−72.98M USDRevenue, FY2021: 2.72M USDRevenue, FY2024: 1.03M USDRevenue, FY2025: 1.63M USDOperating income, FY2021: −51.6M USDOperating income, FY2022: −63.45M USDOperating income, FY2023: −66.1M USDOperating income, FY2024: −53.31M USDOperating income, FY2025: −38.31M USDNet income, FY2021: −8.33M USDNet income, FY2022: −30.59M USDNet income, FY2023: −33.97M USDNet income, FY2024: −30.02M USDNet income, FY2025: −29.67M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.72M USD. Revenue FY2024 1.03M USD. Revenue FY2025 1.63M USD. Operating income FY2021 −51.6M USD. Operating income FY2022 −63.45M USD. Operating income FY2023 −66.1M USD. Operating income FY2024 −53.31M USD. Operating income FY2025 −38.31M USD. Net income FY2021 −8.33M USD. Net income FY2022 −30.59M USD. Net income FY2023 −33.97M USD. Net income FY2024 −30.02M USD. Net income FY2025 −29.67M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.63M USD1.03M USD——2.72M USD
Cost of goods sold900K USD—822K USD——
Gross profit733K USD1.03M USD−822K USD—2.72M USD
Research and development20.21M USD26.68M USD39.62M USD36.61M USD26.48M USD
Selling, general, and administrative19.74M USD23.95M USD26.48M USD26.84M USD27.83M USD
Operating expenses39.04M USD54.34M USD65.28M USD63.45M USD54.32M USD
Interest income827K USD1.76M USD3.3M USD1.25M USD89K USD
Interest expense2.89M USD5.03M USD5.09M USD1.07M USD466K USD
Depreciation and amortization900K USD1.03M USD822K USD548K USD497K USD
Operating income−38.31M USD−53.31M USD−66.1M USD−63.45M USD−51.6M USD
Net income−29.67M USD−30.02M USD−33.97M USD−30.59M USD−8.33M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
-12.05%
11 comparable reports
Latest EPS result
-0.04
Estimate -0.05 · Beat by 20.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.12-0.22-0.31Q1 '25MissQ2 '25MetQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.27, estimate -0.24, surprise -12.50%, Miss. Q2 2025, reported May 13, 2025: actual -0.22, estimate -0.22, surprise 0.00%, Met estimate. Q3 2025, reported Aug 7, 2025: actual -0.18, estimate -0.19, surprise +5.26%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.12, estimate -0.09, surprise -33.33%, Miss. Q1 2026, reported Mar 26, 2026: actual -0.07, estimate -0.03, surprise -133.33%, Miss. Q2 2026, reported May 15, 2026: actual -0.04, estimate -0.06, surprise +33.33%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.04, estimate -0.05, surprise +20.00%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates5.39M3.64M1.89M146.2KQ1 '24No estimateQ1 '25No estimateQ2 '25No estimateQ4 '25EstimateQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2024, reported Mar 20, 2024: actual 2.75M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 1.03M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 13, 2025: actual 172K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual —, estimate 5M USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 26, 2026: actual 1.46M USD, estimate 5M USD, surprise -70.78%, Miss. Q2 2026, reported May 15, 2026: actual 1.71M USD, estimate 1.13M USD, surprise +51.82%, Beat. Q3 2026, reported Aug 13, 2026: actual 1.71M USD, estimate 925K USD, surprise +84.76%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 1.28M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$15.67

1680.68% upside
Past 12 months12-month forecast

Price history unavailable

High $28.00Average $15.67Low $9.00

Recent analyst actions

6 institutions
Maxim GroupmaintainBuy
OppenheimermaintainOutperform
BTIGmaintainBuy
WedbushmaintainOutperform

RANI news

marketbeat.com

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

Rani Therapeutics NASDAQ: RANI outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in…

Read source
globenewswire.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral…

Read source
globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

SAN JOSE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's…

Read source
globenewswire.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of…

Read source
globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with…

Read source
globenewswire.com

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~

Read source

RANI peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding RANI

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.82M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
646.29K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Invesco Nasdaq Biotechnology ETF logoInvesco Nasdaq Biotechnology ETFIBBQ
Market value
5.58K
Weight
0.01%
AUM
94.57M USD
Expense ratio
0.19%
Price / 1D
$36.29+1.37%
ProShares Ultra Nasdaq Biotechnology logoProShares Ultra Nasdaq BiotechnologyBIB
Market value
3.38K
Weight
0.00%
AUM
103.78M USD
Expense ratio
1.19%
Price / 1D
$122.16+2.73%

Continue in GoAI

Research RANI

research.disclaimer